Private Advisor Group’s Telix Pharmaceuticals TLX Stock Holding History

Private Advisor Group’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Buy	197,250 +22,835	+13%	+$233K	0.01%	954
2026 Q1	$1.67M	Buy	174,415 +128,070	+276%	+$976K	0.01%	1134
2025 Q4	$347K	Buy	46,345 +4,233	+10%	+$40.7K	﹤0.01%	2059
2025 Q3	$403K	Buy	42,112 +16,945	+67%	+$208K	﹤0.01%	1898
2025 Q2	$404K	Buy	25,167 +15,027	+148%	+$252K	﹤0.01%	1799
2025 Q1	$170K	Buy	+10,140	New	+$177K	﹤0.01%	2129

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

RBI

Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Private Advisor Group's TLX Position: Q2 2026 in Review

Private Advisor Group increased its Telix Pharmaceuticals (TLX) stake by 13% in Q2 2026, buying an estimated $233K and bringing the position to 197,250 shares worth $2.27M. The position accounts for 0.01% of the portfolio, ranked #954.

Private Advisor Group first reported a position in TLX in Q1 2025 and has held it in 6 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

Private Advisor Group held 197,250 shares of Telix Pharmaceuticals worth $2.27M as of Q2 2026.
Private Advisor Group bought 22,835 Telix Pharmaceuticals shares in Q2 2026, an estimated $233K.
Telix Pharmaceuticals made up 0.01% of Private Advisor Group's portfolio in Q2 2026, its #954 holding.
Private Advisor Group first reported a position in Telix Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.